RVMD β€” REVOLUTION MEDICINES INC

Ownership history in Frazier Life Sciences Management, L.P.  Β·  12 quarters on record

This page tracks every 13F SEC filing in which Frazier Life Sciences Management, L.P. reported a position in REVOLUTION MEDICINES INC (RVMD). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
1.83% (2023 Q3)
πŸ“Š Avg. % of fund
1.59%
πŸ“… First filed
2023 Q1
πŸ“… Last filed
2025 Q4
⏱ Quarters held
12

Position Intelligence

Frazier Life Sciences Management, L.P. Γ— RVMD AI Analytics

πŸ“ˆ Frazier Life Sciences Management, L.P. outperformed the S&P 500 by +37.0% annually on this RVMD position. Average cost basis: $22.52. Maximum drawdown during holding period: –22.0%.

πŸ“ˆ Position Alpha vs SPY
+37.0%
annualised excess return

πŸ”₯ Exceptional β€” beat the S&P 500 by 37.0% per year on this position.
11 quarters analyzed

πŸ’° Entry Quality
$22.52
+253.7% vs current ($79.65)

Best entry: $21.66 (2023 Q1)  Β·  Worst: $27.68 (2023 Q3)

πŸ›‘οΈ Drawdown Resilience
–22.0%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
67%
buy-side decisions

2 adds Β· 1 trim. Bought during 0 of 2 down-price quarters. πŸ“ˆ More buys than sells across the holding period.

πŸ“‘ Position Trajectory
↓ Shrinking
last 4–5 quarters trend

πŸ“‰ Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 1.71% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    RVMD price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 REDUCED 797,455 -200,000 -20.1% 1.71% $63.5M $79.65
2025 Q3 UNCHANGED 997,455 β€” 0% 1.40% $46.6M $46.70
2025 Q2 UNCHANGED 997,455 β€” 0% 1.47% $36.7M $36.79
2025 Q1 UNCHANGED 997,455 β€” 0% 1.61% $35.3M $35.36
2024 Q4 UNCHANGED 997,455 β€” 0% 1.81% $43.6M $43.74
2024 Q3 UNCHANGED 997,455 β€” 0% 1.81% $45.2M $45.35
2024 Q2 UNCHANGED 997,455 β€” 0% 1.81% $38.7M $38.81
2024 Q1 UNCHANGED 997,455 β€” 0% 1.36% $32.1M $32.23
2023 Q4 UNCHANGED 997,455 β€” 0% 1.53% $28.6M $28.68
2023 Q3 ADDED 997,455 +142,971 +16.7% 1.83% $27.6M $27.68
2 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

🏒 Other funds also holding RVMD

As of 2025 Q4 β€” sorted by position size

AIHC Capital Management Ltd 67.21% Park Avenue Institutional Advisers LLC 3Y 7Y 40.5% Paradigm Biocapital Advisors LP 3Y 13.51% Casdin Capital, LLC 3Y 7Y 12.75% DAFNA Capital Management LLC 3Y 7Y 11.18% Alphabet Inc. 3Y 10.33% Logos Global Management LP 3Y 9.63% Checkpoint Capital L.P. 9.21% MIC Capital Management UK LLP 3Y 9.18% BVF INC/IL 3Y 7Y 9.0%
← Back to Frazier Life Sciences Management, L.P. Holdings